Hyperfine (NASDAQ:HYPR) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Hyperfine (NASDAQ:HYPR) posted its earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. The firm had revenue of $5.96 million during the quarter, compared to analyst estimates of $5.84 million. Hyperfine had a negative net margin of 210.75% and a negative return on equity of 97.88%.

Here are the key takeaways from Hyperfine’s conference call:

• Hyperfine reported a record $6.0 million in Q3 revenue, up 73% year over year, with contributions from U.S. hospitals, U.S. offices, and international markets. Gross margin reached a record 56.7%, and revenue grew much faster than operating expenses.
• Operating leverage improved: operating loss narrowed to $7.3 million, while net cash burn fell 29% sequentially to a quarterly low of $5.6 million—below quarterly revenue for the first time. The company ended September with $37.9 million in cash and expects runway into 2028, assuming no additional financing or future debt draws.
• Management reaffirmed 2026 revenue guidance of $20 million–$22 million and net cash burn guidance of $26 million–$28 million, while raising the low end of its gross-margin range to 52.5% from 50%. The revenue outlook was not raised despite the strong quarter; management cited the lumpy nature of capital-equipment sales and a one-time system upgrade that boosted Q4 2025 revenue.
• The company completed enrollment in its Contrast PMR study and remains on track to submit a 510(k) application by year-end 2026; management said clearance could come around Q2 to mid-2027. It expects contrast imaging to broaden use in hospitals and offices, including access to a dedicated reimbursement code in outpatient settings.
• Hyperfine is exploring a brain-health and wellness offering using its existing scanner, with potential software and cloud development rather than major hardware changes. Management characterized this as an emerging opportunity, but does not expect meaningful revenue from it before 2028 or later.

Hyperfine Price Performance

HYPR opened at $0.71 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 5.45 and a current ratio of 6.15. The firm has a market cap of $75.30 million, a P/E ratio of -1.87 and a beta of 1.49. Hyperfine has a fifty-two week low of $0.67 and a fifty-two week high of $1.94. The firm has a 50-day moving average of $0.79 and a 200 day moving average of $1.11.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HYPR. Loop Capital set a $2.00 price objective on shares of Hyperfine in a research report on Tuesday, October 27th. BTIG Research restated a “buy” rating and issued a $2.00 target price on shares of Hyperfine in a research note on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating and issued a $1.60 target price (down from $2.00) on shares of Hyperfine in a report on Monday, August 10th. Finally, Lucid Cap Mkts began coverage on Hyperfine in a research report on Tuesday, October 27th. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hyperfine presently has a consensus rating of “Moderate Buy” and a consensus price target of $2.02.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside.